# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the pric...
JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...
Barclays analyst Peter Lawson maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...
Wedbush analyst David Nierengarten maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Outperform and raises the price t...